Bill Covering Breakthrough Products ‘Step In The Wrong Direction,’ Researchers Say

Researchers from the Brigham and Women’s Hospital and Harvard Medical School argue that the Ensuring Patient Access to Critical Breakthrough Products Act is “a step in the wrong direction.”

"Medicare" written out on wood blocks on a yellow background. A stethescope surrounds the letters in the background.
• Source: Shutterstock

The Ensuring Patient Access to Critical Breakthrough Products Act (HR 1691) would rob the US Center for Medicare and Medicaid Services of its “discretion to say no” to coverage of medical devices, a new opinion piece states.

C. Joseph Ross Daval, Liam Bendicksen and Aaron Kesselheim of Brigham and Women’s Hospital and Harvard Medical School published an article in Nature in September arguing against the Ensuring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.